BIOTRONIK Orsiro Pre-Marketing Registration
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 440 participants.
Also called NCT02870985
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 440 participants
- Registry
-
NCT02870985
-
- Other papers using this trial's data
- Comparison of the Ultrathin Strut, Biodegradable Polymer Sirolimus-eluting Stent With a Durable Polymer Everolimus-eluting Stent in a Chinese Population: The Randomized BIOFLOW VI Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02870985. Randomized; single masking; primary purpose treatment. Start 2015-07-14 (actual); primary completion 2017-04-06 (actual). Results posted on 2024-03-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- BIOTRONIK Orsiro Pre-Marketing Registration
- Acronym
- BIOFLOW-VI
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Coronary Stent
- Lead sponsor
- Biotronik (Beijing) Medical Device Ltd.
Record details
- Record id
cardio:ct-nct02870985- Content hash
3198df180c78183772a08adf8f992c6a0e4162e419ad4df09f62adbbf6cf96b1